Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: An Australian and New Zealand perspective Part 2 New and emerging therapies and their efficacy

Broadley, Simon A.; Barnett, Michael H.; Marriott, Mark; Mason, Deborah F.; Parratt, John; Reddel, Stephen W.; Shaw, Cameron P.; Slee, Mark; Spies, Judith; Taylor, Bruce V.; Carroll, William M.; Kilpatrick, Trevor J.; Boggild, Mike; King, John; McCombe, Pamela A.; Pollard, John D.; Willoughby, Ernest; Brew, Bruce J.; Butzkueven, Helmut; Heard, Robert; Hodgkinson, Suzanne; Kermode, Allan G.; Lechner-Scott, Jeannette; Macdonell, Richard A. L.

Title: Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: An Australian and New Zealand perspective Part 2 New and emerging therapies and their efficacy
Creator: Broadley, Simon A.; Barnett, Michael H.; Marriott, Mark; Mason, Deborah F.; Parratt, John; Reddel, Stephen W.; Shaw, Cameron P.; Slee, Mark; Spies, Judith; Taylor, Bruce V.; Carroll, William M.; Kilpatrick, Trevor J.; Boggild, Mike; King, John; McCombe, Pamela A.; Pollard, John D.; Willoughby, Ernest; Brew, Bruce J.; Butzkueven, Helmut; Heard, Robert; Hodgkinson, Suzanne; Kermode, Allan G.; Lechner-Scott, Jeannette; Macdonell, Richard A. L.
Relation: Journal of Clinical Neuroscience Vol. 21, Issue 11, p. 1847-1856
Publisher Link: http://dx.doi.org/10.1016/j.jocn.2014.01.018
Publisher: Elsevier
Resource Type: journal article
Date: 2014
Description: In Part 2 of this three part review of multiple sclerosis (MS) treatment with a particular focus on the Australian and New Zealand perspective, we review the newer therapies that have recently become available and emerging therapies that have now completed phase III clinical trial programs. We go on to compare the relative efficacies of these newer and emerging therapies alongside the existing therapies. The effectiveness of ß-interferon in the treatment of different stages and the different disease courses of MS is critically reviewed with the conclusion that the absolute level of response in term of annualised relapse rates (where relapses occur) and MRI activity are similar, but are disappointing in terms of sustained disability progression for progressive forms of the disease. Finally we review the controversial area of combination therapy for MS. Whilst it remains the case that we have no cure or means of preventing MS, we do have a range of effective therapies that when used appropriately and early in the disease course can have a significant impact on short term and longer term outcomes
Subject: evidence-based medicine; guideline; multiple sclerosis; review; treatment
Identifier: http://hdl.handle.net/1959.13/1294853
Identifier: uon:18887
Identifier: ISSN:0967-5868
Language: eng
Reviewed

Hits: 7955
Visitors: 4301
Downloads: 0

		Thumbnail	File	Description	Size	Format